960 x 350_41

体外筛选

体外筛选在候选药物优化 ADME 特性中发挥关键作用。提前确定最有前景的候选药物可加速开发周期,降低成本,简化药物发现流程,指导后续的临床前和临床研究。Q2 Solutions 高自动化体外 ADME 实验室提供一系列高通量 ADME 筛选服务,以支持药物发现的先导优化阶段,包括代谢稳定性、细胞渗透性测定和抑制细胞色素 P450 酶的风险评估。

我们的 ADME 筛选组件包和 LC/MS 生物分析能力可支持您的体外和药代动力学(PK)检测


q2lab solutions images_0014_Layer 2

早期先导化合物的 ADME 筛选服务包

捆绑筛选检测,以在药物发现中加速候选药物选择

q2lab solutions images_0001_Layer 15

高通量 ADME 服务

加速临床前研究的能力

相关思想领袖见解


Quantification of the Polydisperse Heparin Analog Dociparstat by Signature Disaccharide Analysis in the Presence of Concomitant Enoxaparin Dosing in Support of a Phase 2/3 Study in Patients with Severe COVID-19

Analysis of a polydisperse heparin analog therapeutic (CX-01, Dociparstat) was conducted in human plasma by signature disaccharide (NS6S) analysis, with NS6S being unique to CX-01 in native human...

Hybrid assays: an interview with Barry Jones and Adriane Spytko

In this podcast Barry Jones (Director, LC–MS Biologics and Biomarkers at Q² Solutions) and Adriane Spytko (Manager, LC–MS Biologics at Q² Solutions; both NY, USA) discuss hybrid assays using both...

Bridging the LBA and LC−MS disciplines for hybrid assays

The increasing complexity of large molecule therapeutics has driven the need for additional approaches to quantitation in regulated bioanalysis where challenges with traditional ligand binding assays...